In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...

Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today ...

Our editors also may be in touch with follow-up questions. Public Storage is a well-known brand in the self-storage industry. They have a large network of facilities, and they’re known for ...

Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $12.60 million for the quarter, compared to the consensus estimate ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

In recent transactions disclosed by Mersana Therapeutics, Inc. (NASDAQ:MRSN), Timothy B. Lowinger, the company's Senior Vice President and Chief Science & Technology Officer, sold shares of common ...